Skip to content
Screener

Similar metrics at other companies

Robert Half logo
RHIProtiviti — Other
$49.61M-6.0%
Robert Half logo
RHIPermanent placement talent solutions — Other
$16.75M-13.4%
Robert Half logo
RHITotal contract talent solutions — Other
$65.93M-4.8%
The J.M. Smucker Company logo
SJMOther — Other
$400K+105%
TFI
TFINBanking — Other
$2.91M-9.3%
TFI
TFINFactoring — Other
$567K-79.5%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026 / Affordable MedicinesThree Months Ended June 30, 2026 / SpecialtyThree Months Ended June 30, 2025 / Affordable MedicinesThree Months Ended June 30, 2025 / Specialty
Employee compensation and benefits$12,016$1,326$14,693$1,279
Materials and supplies8,7961,0228,108450
Product development and studies (1)(89)2,6157562,371
In-licensing and upfront milestones3,5006,350
Facilities costs1,479301,793735
Regulatory fees1,3342,932
Other (2)5,9871,0017,2671,230
Total$33,023$5,994$41,899$6,065

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s specialty — other?
Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — other of $1M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s specialty — other changed year-over-year?
Amneal Pharmaceuticals, Inc.'s specialty — other decreased by 18.6% year-over-year, from $1.23M to $1M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — other?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — other has grown at a 1.1% compound annual growth rate (CAGR), from $5.41M to $5.58M.
What does specialty — other mean?
Aggregates minor or miscellaneous operational costs that are not captured in specific functional categories within the specialty segment. It is used to track residual overhead and administrative expenses.

Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude